Treatment options for prehypertension

Shawna D. Nesbitt

doi:10.1097/MNH.0b013e3280c8eebe

Treatment options for prehypertension

Shawna D. Nesbitt

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

PURPOSE OF REVIEW: Prehypertension is a recognized stage of blood pressure but treatment standards have not yet been established. This review will focus on the treatment considerations in prehypertension. RECENT FINDINGS: Previous approaches to prehypertensive blood pressure have focused on the role of nonpharmacologic modalities alone. The recently published Trial of Preventing Hypertension (TROPHY) is the first study of pharmacologic intervention in this category of blood pressure. SUMMARY: TROPHY forged new territory in the area of pharmacologic treatment for prehypertension. The safety and tolerability of the angiotensin receptor blocker treatment in the trial offer a new option to clinicians attempting to avoid the ravages of hypertension in the patients they treat. Furthermore the stage is properly set for additional research in treatments for prehypertension.

Original language	English (US)
Pages (from-to)	250-255
Number of pages	6
Journal	Current opinion in nephrology and hypertension
Volume	16
Issue number	3
DOIs	https://doi.org/10.1097/MNH.0b013e3280c8eebe
State	Published - May 2007

Keywords

Angiotensin receptor blocker
Candesartan cilexetil
High normal blood pressure
Lifestyle modification
Prehypertension

ASJC Scopus subject areas

Internal Medicine
Nephrology

Access to Document

10.1097/MNH.0b013e3280c8eebe

Cite this

@article{788cc20094eb4fb68a6ea5c7b7cbe5af,

title = "Treatment options for prehypertension",

abstract = "PURPOSE OF REVIEW: Prehypertension is a recognized stage of blood pressure but treatment standards have not yet been established. This review will focus on the treatment considerations in prehypertension. RECENT FINDINGS: Previous approaches to prehypertensive blood pressure have focused on the role of nonpharmacologic modalities alone. The recently published Trial of Preventing Hypertension (TROPHY) is the first study of pharmacologic intervention in this category of blood pressure. SUMMARY: TROPHY forged new territory in the area of pharmacologic treatment for prehypertension. The safety and tolerability of the angiotensin receptor blocker treatment in the trial offer a new option to clinicians attempting to avoid the ravages of hypertension in the patients they treat. Furthermore the stage is properly set for additional research in treatments for prehypertension.",

keywords = "Angiotensin receptor blocker, Candesartan cilexetil, High normal blood pressure, Lifestyle modification, Prehypertension",

author = "Nesbitt, {Shawna D.}",

year = "2007",

month = may,

doi = "10.1097/MNH.0b013e3280c8eebe",

language = "English (US)",

volume = "16",

pages = "250--255",

journal = "Current opinion in nephrology and hypertension",

issn = "1062-4821",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Treatment options for prehypertension

AU - Nesbitt, Shawna D.

PY - 2007/5

Y1 - 2007/5

N2 - PURPOSE OF REVIEW: Prehypertension is a recognized stage of blood pressure but treatment standards have not yet been established. This review will focus on the treatment considerations in prehypertension. RECENT FINDINGS: Previous approaches to prehypertensive blood pressure have focused on the role of nonpharmacologic modalities alone. The recently published Trial of Preventing Hypertension (TROPHY) is the first study of pharmacologic intervention in this category of blood pressure. SUMMARY: TROPHY forged new territory in the area of pharmacologic treatment for prehypertension. The safety and tolerability of the angiotensin receptor blocker treatment in the trial offer a new option to clinicians attempting to avoid the ravages of hypertension in the patients they treat. Furthermore the stage is properly set for additional research in treatments for prehypertension.

AB - PURPOSE OF REVIEW: Prehypertension is a recognized stage of blood pressure but treatment standards have not yet been established. This review will focus on the treatment considerations in prehypertension. RECENT FINDINGS: Previous approaches to prehypertensive blood pressure have focused on the role of nonpharmacologic modalities alone. The recently published Trial of Preventing Hypertension (TROPHY) is the first study of pharmacologic intervention in this category of blood pressure. SUMMARY: TROPHY forged new territory in the area of pharmacologic treatment for prehypertension. The safety and tolerability of the angiotensin receptor blocker treatment in the trial offer a new option to clinicians attempting to avoid the ravages of hypertension in the patients they treat. Furthermore the stage is properly set for additional research in treatments for prehypertension.

KW - Angiotensin receptor blocker

KW - Candesartan cilexetil

KW - High normal blood pressure

KW - Lifestyle modification

KW - Prehypertension

UR - http://www.scopus.com/inward/record.url?scp=34247263683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247263683&partnerID=8YFLogxK

U2 - 10.1097/MNH.0b013e3280c8eebe

DO - 10.1097/MNH.0b013e3280c8eebe

M3 - Review article

C2 - 17420669

AN - SCOPUS:34247263683

SN - 1062-4821

VL - 16

SP - 250

EP - 255

JO - Current opinion in nephrology and hypertension

JF - Current opinion in nephrology and hypertension

IS - 3

ER -

Treatment options for prehypertension

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this